NCT03391193View on ClinicalTrials.gov

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

PHASE3CompletedINTERVENTIONAL
Enrollment

301

Participants

Timeline

Start Date

December 19, 2017

Primary Completion Date

March 28, 2018

Study Completion Date

August 25, 2018

Conditions
Influenza
Interventions
BIOLOGICAL

Multi-dose Quadrivalent Influenza Vaccine

0.5 mL, intramuscular

BIOLOGICAL

Single-dose Quadrivalent Influenza Vaccine

0.5 mL, intramuscular

Trial Locations (3)

55075

Sanofi Pasteur Investigational Site 0002, Ecatepec de Morelos

62290

Sanofi Pasteur Investigational Site 0001, Cuernavaca

04530

Sanofi Pasteur Investigational Site 0003, Mexico City

All Listed Sponsors
lead

Sanofi Pasteur, a Sanofi Company

INDUSTRY

NCT03391193 - Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine | Biotech Hunter | Biotech Hunter